PROSPA GROUP LIMITED. - Announcements

0.00%

44.5¢

Currently unlisted. Proposed listing date: TUESDAY, 11 JUNE 2019, 12:00PM ##

Prospa Group Ltd is an Australia-based financial technology company. The Company is a... Prospa Group Ltd is an Australia-based financial technology company. The Company is a provider of cash flow products and services. The Company’s operations consist primarily of the provision of loans to small businesses in Australia and New Zealand. It facilitates referrals and customer acquisitions from a network of distribution partners, including finance brokers, aggregator networks, online affiliates, accountants and other advisers. The purpose-built credit decision engine (CDE) enables approvals and adoption of dynamic risk-based pricing, where interest rates associated with a facility are based on credit risk assessments for individual customers. Its CDE allows the business to quickly evaluate opportunities and potential risks across the portfolio. Its product suite includes a Small Business Loan and a Line of Credit. The Company has launched Prospa Plus Business Loans, offering higher credit quality for small to medium enterprises (SME).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PGL	EPO to Grant Sulfated Oligosaccharide Derivatives Patent	PRICE SENSITIVE	21/07/14	67.34KB	Share
PGL	Medigen Schedules PI-88 Interim Patient Analysis in July		09/07/14	69.17KB	Share
PGL	Change of Head Office Address		28/05/14	66.62KB	Share
PGL	Change of Director's Interest Notice		19/05/14	129.01KB	Share
PGL	PG545 Phase 1 Clinical Trial Update	PRICE SENSITIVE	15/05/14	106.94KB	Share
PGL	Changes to Management & Corporate Office Address	PRICE SENSITIVE	14/05/14	68.75KB	Share
PGL	Medigen Expects PI-88 Interim Patient Data in May 2014	PRICE SENSITIVE	08/05/14	69.59KB	Share
PGL	Medigen Engages PharmaSynth to Manufacture PI-88	PRICE SENSITIVE	29/04/14	70.22KB	Share
PGL	Notice of Allowance of US patent for PG545	PRICE SENSITIVE	28/04/14	67.56KB	Share
PGL	PG545 Data Presented at AACR Conference	PRICE SENSITIVE	09/04/14	156.22KB	Share
PGL	Issue of Unlisted Options under ESOP		02/04/14	274.72KB	Share
PGL	Response to ASX Price Query	PRICE SENSITIVE	17/03/14	285.41KB	Share
PGL	Change of Director's Interest Notice		13/03/14	229.42KB	Share
PGL	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/14	569.26KB	Share
PGL	PG545 Data Presented at Lorne Cancer Conference		13/02/14	91.43KB	Share
PGL	Receipt of R& D Tax Incentive Refund		31/01/14	84.62KB	Share
PGL	Response to ASX Price Query	PRICE SENSITIVE	30/01/14	136.43KB	Share
PGL	PATRON Trial Completes Patient Recruitment	PRICE SENSITIVE	30/12/13	154.47KB	Share
PGL	Change of Director's Interest Notice		20/12/13	218.82KB	Share
PGL	R&D Tax Incentive Refund	PRICE SENSITIVE	17/12/13	72.68KB	Share
PGL	2013 Form 20-F/A Filed with the US SEC		13/12/13	1013.41KB	Share
PGL	Change of Director's Interest Notice		06/12/13	92.97KB	Share
PGL	Beta Therapeutics Assignment Agreement	PRICE SENSITIVE	03/12/13	88.15KB	Share
PGL	Initial Director's Interest Notice - Hongjen Chang		02/12/13	69.49KB	Share
PGL	Final Director's Interest Notice - Stuart James		29/11/13	70.65KB	Share
PGL	Appointment of Director and Chair		29/11/13	155.19KB	Share
PGL	Results of Annual General Meeting		28/11/13	166.97KB	Share
PGL	2013 Annual General Meeting Address	PRICE SENSITIVE	28/11/13	1.16MB	Share
PGL	Change to Board of Directors		27/11/13	150.69KB	Share
PGL	2013 Form 20-F Filed with the US SEC		01/11/13	2.79MB	Share
PGL	PG545 Phase 1 Cancer Trial Update	PRICE SENSITIVE	29/10/13	160.55KB	Share
PGL	Notice of Annual General Meeting/Proxy Form		25/10/13	638.38KB	Share
PGL	Change to Acting Managing Director's Terms of Employment	PRICE SENSITIVE	21/10/13	154.17KB	Share
PGL	Appendix 3B - Issue of Unlisted Options		03/10/13	278.97KB	Share
PGL	Annual Report to shareholders		27/09/13	4.93MB	Share
PGL	Preliminary Final Report	PRICE SENSITIVE	27/08/13	1.27MB	Share
PGL	Update on PG545 Preclinical Program	PRICE SENSITIVE	22/08/13	96.46KB	Share
PGL	PI-88 Phase III Update		22/07/13	153.88KB	Share
PGL	Final Director's Interest Notice		15/07/13	73.72KB	Share
PGL	Initial Director's Interest Notice		15/07/13	70.75KB	Share
PGL	Board and Senior Management Changes	PRICE SENSITIVE	12/07/13	160.29KB	Share
PGL	PG545 Preclinical Data Published in Molecular Cancer Therape		09/07/13	107.8KB	Share
PGL	Ceasing to be a substantial holder		05/06/13	191.87KB	Share
PGL	Ceasing to be a substantial holder		30/05/13	863.95KB	Share
PGL	Change in substantial holding		29/05/13	338.19KB	Share
PGL	Becoming a substantial holder		29/05/13	242.56KB	Share
PGL	Share Placement - Notice under Section 708A(5)(e)		29/05/13	150.58KB	Share
PGL	Share Placement & Appendix 3B	PRICE SENSITIVE	27/05/13	277.58KB	Share
PGL	Change in substantial holding		24/05/13	279.67KB	Share
PGL	Change of Director's Interest Notice		22/05/13	84.56KB	Share
PGL	Change of Director's Interest Notice		22/05/13	83.98KB	Share
PGL	Rights Issue - Notice under Section 708A(5)(e)		22/05/13	86.12KB	Share
PGL	Rights Issue - Share Allotment		22/05/13	226.26KB	Share
PGL	Rights Issue - Notification of Subscriptions		20/05/13	153.84KB	Share
PGL	Dispatch of Non-Renounceable Rights Issue Offer Document		01/05/13	148KB	Share
PGL	Rights Issue - Notice to Ineligible Shareholders		18/04/13	159.96KB	Share
PGL	Rights Issue - Notice to Eligible Shareholders		18/04/13	177.9KB	Share
PGL	Rights Issue - Letter to Option Holders		17/04/13	153.96KB	Share
PGL	Rights Issue - Notice Under Section 708AA		17/04/13	143.19KB	Share
PGL	Offer Document - Non-Renounceable Rights Issue	PRICE SENSITIVE	17/04/13	224.18KB	Share
PGL	Appendix 3B - Non Renounceable Pro Rata Rights Issue		16/04/13	118.84KB	Share
PGL	Non Renounceable Pro Rata Rights Issue	PRICE SENSITIVE	16/04/13	161.07KB	Share
PGL	Change of Director's Interest Notice		27/03/13	278.93KB	Share
PGL	Change of Director's Interest Notice		22/03/13	279.82KB	Share
PGL	Change of Director's Interest Notice		15/03/13	85.97KB	Share
PGL	Progen Pharmaceuticals signs PG545 License	PRICE SENSITIVE	01/03/13	84.22KB	Share
PGL	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/13	287.63KB	Share
PGL	Receipt of R&D Tax Incentive Refund	PRICE SENSITIVE	31/01/13	146.86KB	Share
PGL	Queensland Storm - Operations Unaffected		31/01/13	145.92KB	Share
PGL	R&D Tax Incentive Refund	PRICE SENSITIVE	14/01/13	147.8KB	Share
PGL	Progen Pharmaceuticals Ltd signs Binding License Term Sheet	PRICE SENSITIVE	28/12/12	88.03KB	Share
PGL	Appendix 3Y		17/12/12	272.34KB	Share
PGL	Appendix 3Y		06/12/12	280.68KB	Share
PGL	2012 Form 20-F Filed with the US SEC		04/12/12	2.83MB	Share
PGL	Results of Meeting		29/11/12	149.92KB	Share
PGL	AGM Capital Raising Presentation	PRICE SENSITIVE	29/11/12	299.65KB	Share
PGL	Chairman's Address to Shareholders		29/11/12	156.06KB	Share
PGL	Notice of Annual General Meeting/Proxy Form		25/10/12	1.41MB	Share
PGL	PI-88 Phase II Melanoma Clinical Study Results	PRICE SENSITIVE	17/10/12	139.22KB	Share
PGL	Company Secretary Resignation		12/10/12	81.83KB	Share
PGL	Change of Director's Interest Notice		01/10/12	408.34KB	Share
PGL	Annual Report to shareholders		28/09/12	4.5MB	Share
PGL	PI-88 Phase III Update	PRICE SENSITIVE	27/09/12	28.41KB	Share
PGL	Appendix 3Y		25/09/12	79.01KB	Share
PGL	PG545 Update	PRICE SENSITIVE	21/09/12	82.82KB	Share
PGL	Appendix 3Y		12/09/12	79.18KB	Share
PGL	Preliminary Final Report	PRICE SENSITIVE	31/08/12	485.8KB	Share
PGL	Company Secretary Appointment		21/08/12	81.92KB	Share
PGL	Progen Pharmaceuticals Granted Additional US Patent	PRICE SENSITIVE	17/07/12	82.68KB	Share
PGL	Progen Pharmaceuticals Granted Australian Patent	PRICE SENSITIVE	30/05/12	82.74KB	Share
PGL	Progen Presents PG545 at AACR Meeting in Chicago	PRICE SENSITIVE	04/04/12	88.4KB	Share
PGL	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/12	242.08KB	Share
PGL	Progen Licensee Receives IND Approval in China for PI-88	PRICE SENSITIVE	31/01/12	86.22KB	Share
PGL	Appendix 3Y		03/01/12	74.61KB	Share
PGL	PG545 Update	PRICE SENSITIVE	21/12/11	83.6KB	Share
PGL	Change of Director's Interest Notice		05/12/11	71.3KB	Share
PGL	Results of Meeting		30/11/11	119.04KB	Share
PGL	Chairman's Address - 2011 AGM		30/11/11	91.15KB	Share
PGL	2011 Form 20-F Filed with US SEC		30/11/11	909.04KB	Share
PGL	Progen Presents PG545 at AACR Cancer Conference		14/11/11	85.67KB	Share

PGL EPO to Grant Sulfated Oligosaccharide Derivatives Patent
21/07/14	PRICE SENSITIVE	67.34KB	Share
PGL Medigen Schedules PI-88 Interim Patient Analysis in July
09/07/14		69.17KB	Share
PGLChange of Head Office Address
28/05/14		66.62KB	Share
PGLChange of Director's Interest Notice
19/05/14		129.01KB	Share
PGLPG545 Phase 1 Clinical Trial Update
15/05/14	PRICE SENSITIVE	106.94KB	Share
PGLChanges to Management & Corporate Office Address
14/05/14	PRICE SENSITIVE	68.75KB	Share
PGLMedigen Expects PI-88 Interim Patient Data in May 2014
08/05/14	PRICE SENSITIVE	69.59KB	Share
PGLMedigen Engages PharmaSynth to Manufacture PI-88
29/04/14	PRICE SENSITIVE	70.22KB	Share
PGLNotice of Allowance of US patent for PG545
28/04/14	PRICE SENSITIVE	67.56KB	Share
PGLPG545 Data Presented at AACR Conference
09/04/14	PRICE SENSITIVE	156.22KB	Share
PGLIssue of Unlisted Options under ESOP
02/04/14		274.72KB	Share
PGLResponse to ASX Price Query
17/03/14	PRICE SENSITIVE	285.41KB	Share
PGLChange of Director's Interest Notice
13/03/14		229.42KB	Share
PGLHalf Yearly Report and Accounts
27/02/14	PRICE SENSITIVE	569.26KB	Share
PGLPG545 Data Presented at Lorne Cancer Conference
13/02/14		91.43KB	Share
PGLReceipt of R& D Tax Incentive Refund
31/01/14		84.62KB	Share
PGLResponse to ASX Price Query
30/01/14	PRICE SENSITIVE	136.43KB	Share
PGLPATRON Trial Completes Patient Recruitment
30/12/13	PRICE SENSITIVE	154.47KB	Share
PGLChange of Director's Interest Notice
20/12/13		218.82KB	Share
PGLR&D Tax Incentive Refund
17/12/13	PRICE SENSITIVE	72.68KB	Share
PGL2013 Form 20-F/A Filed with the US SEC
13/12/13		1013.41KB	Share
PGLChange of Director's Interest Notice
06/12/13		92.97KB	Share
PGLBeta Therapeutics Assignment Agreement
03/12/13	PRICE SENSITIVE	88.15KB	Share
PGLInitial Director's Interest Notice - Hongjen Chang
02/12/13		69.49KB	Share
PGLFinal Director's Interest Notice - Stuart James
29/11/13		70.65KB	Share
PGLAppointment of Director and Chair
29/11/13		155.19KB	Share
PGLResults of Annual General Meeting
28/11/13		166.97KB	Share
PGL2013 Annual General Meeting Address
28/11/13	PRICE SENSITIVE	1.16MB	Share
PGLChange to Board of Directors
27/11/13		150.69KB	Share
PGL2013 Form 20-F Filed with the US SEC
01/11/13		2.79MB	Share
PGLPG545 Phase 1 Cancer Trial Update
29/10/13	PRICE SENSITIVE	160.55KB	Share
PGLNotice of Annual General Meeting/Proxy Form
25/10/13		638.38KB	Share
PGLChange to Acting Managing Director's Terms of Employment
21/10/13	PRICE SENSITIVE	154.17KB	Share
PGLAppendix 3B - Issue of Unlisted Options
03/10/13		278.97KB	Share
PGLAnnual Report to shareholders
27/09/13		4.93MB	Share
PGLPreliminary Final Report
27/08/13	PRICE SENSITIVE	1.27MB	Share
PGLUpdate on PG545 Preclinical Program
22/08/13	PRICE SENSITIVE	96.46KB	Share
PGLPI-88 Phase III Update
22/07/13		153.88KB	Share
PGLFinal Director's Interest Notice
15/07/13		73.72KB	Share
PGLInitial Director's Interest Notice
15/07/13		70.75KB	Share
PGLBoard and Senior Management Changes
12/07/13	PRICE SENSITIVE	160.29KB	Share
PGLPG545 Preclinical Data Published in Molecular Cancer Therape
09/07/13		107.8KB	Share
PGLCeasing to be a substantial holder
05/06/13		191.87KB	Share
PGLCeasing to be a substantial holder
30/05/13		863.95KB	Share
PGLChange in substantial holding
29/05/13		338.19KB	Share
PGLBecoming a substantial holder
29/05/13		242.56KB	Share
PGLShare Placement - Notice under Section 708A(5)(e)
29/05/13		150.58KB	Share
PGLShare Placement & Appendix 3B
27/05/13	PRICE SENSITIVE	277.58KB	Share
PGLChange in substantial holding
24/05/13		279.67KB	Share
PGLChange of Director's Interest Notice
22/05/13		84.56KB	Share
PGLChange of Director's Interest Notice
22/05/13		83.98KB	Share
PGLRights Issue - Notice under Section 708A(5)(e)
22/05/13		86.12KB	Share
PGLRights Issue - Share Allotment
22/05/13		226.26KB	Share
PGLRights Issue - Notification of Subscriptions
20/05/13		153.84KB	Share
PGLDispatch of Non-Renounceable Rights Issue Offer Document
01/05/13		148KB	Share
PGLRights Issue - Notice to Ineligible Shareholders
18/04/13		159.96KB	Share
PGLRights Issue - Notice to Eligible Shareholders
18/04/13		177.9KB	Share
PGLRights Issue - Letter to Option Holders
17/04/13		153.96KB	Share
PGLRights Issue - Notice Under Section 708AA
17/04/13		143.19KB	Share
PGLOffer Document - Non-Renounceable Rights Issue
17/04/13	PRICE SENSITIVE	224.18KB	Share
PGLAppendix 3B - Non Renounceable Pro Rata Rights Issue
16/04/13		118.84KB	Share
PGLNon Renounceable Pro Rata Rights Issue
16/04/13	PRICE SENSITIVE	161.07KB	Share
PGLChange of Director's Interest Notice
27/03/13		278.93KB	Share
PGLChange of Director's Interest Notice
22/03/13		279.82KB	Share
PGLChange of Director's Interest Notice
15/03/13		85.97KB	Share
PGLProgen Pharmaceuticals signs PG545 License
01/03/13	PRICE SENSITIVE	84.22KB	Share
PGLHalf Yearly Report and Accounts
28/02/13	PRICE SENSITIVE	287.63KB	Share
PGLReceipt of R&D Tax Incentive Refund
31/01/13	PRICE SENSITIVE	146.86KB	Share
PGLQueensland Storm - Operations Unaffected
31/01/13		145.92KB	Share
PGLR&D Tax Incentive Refund
14/01/13	PRICE SENSITIVE	147.8KB	Share
PGLProgen Pharmaceuticals Ltd signs Binding License Term Sheet
28/12/12	PRICE SENSITIVE	88.03KB	Share
PGLAppendix 3Y
17/12/12		272.34KB	Share
PGLAppendix 3Y
06/12/12		280.68KB	Share
PGL2012 Form 20-F Filed with the US SEC
04/12/12		2.83MB	Share
PGLResults of Meeting
29/11/12		149.92KB	Share
PGLAGM Capital Raising Presentation
29/11/12	PRICE SENSITIVE	299.65KB	Share
PGLChairman's Address to Shareholders
29/11/12		156.06KB	Share
PGLNotice of Annual General Meeting/Proxy Form
25/10/12		1.41MB	Share
PGLPI-88 Phase II Melanoma Clinical Study Results
17/10/12	PRICE SENSITIVE	139.22KB	Share
PGLCompany Secretary Resignation
12/10/12		81.83KB	Share
PGLChange of Director's Interest Notice
01/10/12		408.34KB	Share
PGLAnnual Report to shareholders
28/09/12		4.5MB	Share
PGLPI-88 Phase III Update
27/09/12	PRICE SENSITIVE	28.41KB	Share
PGLAppendix 3Y
25/09/12		79.01KB	Share
PGLPG545 Update
21/09/12	PRICE SENSITIVE	82.82KB	Share
PGLAppendix 3Y
12/09/12		79.18KB	Share
PGLPreliminary Final Report
31/08/12	PRICE SENSITIVE	485.8KB	Share
PGLCompany Secretary Appointment
21/08/12		81.92KB	Share
PGLProgen Pharmaceuticals Granted Additional US Patent
17/07/12	PRICE SENSITIVE	82.68KB	Share
PGLProgen Pharmaceuticals Granted Australian Patent
30/05/12	PRICE SENSITIVE	82.74KB	Share
PGLProgen Presents PG545 at AACR Meeting in Chicago
04/04/12	PRICE SENSITIVE	88.4KB	Share
PGLHalf Yearly Report and Accounts
28/02/12	PRICE SENSITIVE	242.08KB	Share
PGLProgen Licensee Receives IND Approval in China for PI-88
31/01/12	PRICE SENSITIVE	86.22KB	Share
PGLAppendix 3Y
03/01/12		74.61KB	Share
PGLPG545 Update
21/12/11	PRICE SENSITIVE	83.6KB	Share
PGLChange of Director's Interest Notice
05/12/11		71.3KB	Share
PGLResults of Meeting
30/11/11		119.04KB	Share
PGLChairman's Address - 2011 AGM
30/11/11		91.15KB	Share
PGL2011 Form 20-F Filed with US SEC
30/11/11		909.04KB	Share
PGLProgen Presents PG545 at AACR Cancer Conference
14/11/11		85.67KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.